DGS Capital Management LLC Has $4.32 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

DGS Capital Management LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,737 shares of the company’s stock after selling 582 shares during the quarter. Novo Nordisk A/S makes up 1.7% of DGS Capital Management LLC’s holdings, making the stock its 7th biggest holding. DGS Capital Management LLC’s holdings in Novo Nordisk A/S were worth $4,318,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. First American Trust FSB increased its holdings in Novo Nordisk A/S by 6.1% in the fourth quarter. First American Trust FSB now owns 50,229 shares of the company’s stock valued at $5,196,000 after purchasing an additional 2,868 shares during the period. Private Client Services LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $381,000. Keel Point LLC raised its holdings in Novo Nordisk A/S by 7.8% during the 4th quarter. Keel Point LLC now owns 6,724 shares of the company’s stock worth $696,000 after purchasing an additional 489 shares during the last quarter. Bison Wealth LLC boosted its stake in shares of Novo Nordisk A/S by 27.1% in the 4th quarter. Bison Wealth LLC now owns 7,571 shares of the company’s stock valued at $783,000 after purchasing an additional 1,613 shares during the last quarter. Finally, Hoxton Planning & Management LLC increased its position in shares of Novo Nordisk A/S by 4.9% during the fourth quarter. Hoxton Planning & Management LLC now owns 3,632 shares of the company’s stock worth $376,000 after buying an additional 171 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on NVO shares. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. BMO Capital Markets started coverage on Novo Nordisk A/S in a report on Friday. They issued an “outperform” rating and a $163.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Monday, April 1st. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Up 0.1 %

Novo Nordisk A/S stock traded up $0.07 during mid-day trading on Tuesday, reaching $123.97. The stock had a trading volume of 1,755,169 shares, compared to its average volume of 4,913,317. The firm has a market capitalization of $556.32 billion, a PE ratio of 45.68, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The stock’s 50-day simple moving average is $126.04 and its 200-day simple moving average is $110.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.33 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.